NCT00363636 A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL) Status TERMINATED Phase PHASE3
NCT00344786 Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL Status TERMINATED Phase PHASE1
NCT00319930 Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL Status TERMINATED Phase PHASE1
NCT00301002 Study to Evaluate the Efficacy of Alefacept to Treat Palmar Plantar Pustulosis Status COMPLETED Phase PHASE2
NCT00298272 Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis Status TERMINATED Phase PHASE2
NCT00292422 Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis Status COMPLETED Phase PHASE2
NCT00290511 Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma Status COMPLETED Phase PHASE2
NCT00288990 A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis Status COMPLETED Phase N/A
NCT00280956 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease Status COMPLETED Phase PHASE4
NCT00280241 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia Status COMPLETED Phase PHASE2
NCT00246324 Safety and Efficacy Study of Doxycycline in Combination With Interferon-B-1a to Treat Multiple Sclerosis Status COMPLETED Phase PHASE4
NCT00242268 A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis Status UNKNOWN Phase PHASE3